Pressemeldinger

16-10-2014 14:49 CEST Shire Norge Fra september 2014 er det nye ADHD-medikamentet Elvanse (lisdeksamfetamindimesilat) tilgjengelig på blå resept i Norge.1 Statens Legemiddelverk har godkjent Elvanse for barn i alderen 6 år og eldre når dagens standardbehandling med metylfenidat regnes som klinisk utilstrekkelig. Ordningen gjelder også for ungdom med vedvarende symptomer i voksen alder som har vist klar nytte av behandlingen.

14-10-2014 14:08 CEST Bristol-Myers Squibb

PLEGRIDY™ (PEGINTERFERON BETA-1A) TWO-YEAR DATA CONFIRM MAINTENANCE OF EFFICACY AND SAFETY IN MULTIPLE SCLEROSIS PATIENTS

30-09-2014 10:08 CEST Biogen Idec Norway AS – Results Presented at Joint ACTRIMS-ECTRIMS Meeting Show Patients Continuously Treated with PLEGRIDY Over Two Years Demonstrate Improvement in Clinical and MRI Outcomes –

NEW DATA FROM ENDORSE SHOW POSITIVE RESULTS CONTINUED OVER FIVE YEARS WITH TECFIDERA® (DIMETHYL FUMARATE)

30-09-2014 10:00 CEST Biogen Idec Norway AS – Long-term Favorable Safety Profile Sustained in Patients Treated with TECFIDERA – – Positive Clinical and MRI Outcomes in Newly Diagnosed Patients –

29-09-2014 09:17 CEST Bristol-Myers Squibb

26-09-2014 16:49 CEST Gilead Gilead Sciences, Inc. (Nasdaq: GILD) kunngjorde i dag at Komitéen for legemidler til mennesker (CHMP), tilknyttet EUs legemiddeltilsyn, har kommet med en positiv uttalelse vedrørende selskapets søknad om markedsføringstillatelse (MAA) for Harvoni ®.

European Commission Grants Marketing Authorization for Gilead’s Zydelig (idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma

26-09-2014 08:36 CEST Gilead The European Commission has granted marketing authorization for Zydelig® (idelalisib), 150 mg tablets, a first-in-class oral treatment for two incurable blood cancers – chronic lymphocytic leukemia and follicular lymphoma. "Zydelig is a welcomed treatment option that offers a new approach in the management of these cancers," said Professor Peter Hillmen, Leeds Teaching Hospitals NHS Trust.

PLEGRIDY™ (PEGINTERFERON BETA-1A) APPROVED IN THE EUROPEAN UNION FOR THE TREATMENT OF MULTIPLE SCLEROSIS

11-08-2014 14:59 CEST Biogen Idec Norway AS – Reduces Relapses, Disability Progression, and MRI Brain Lesions, with a Favorable Safety Profile Consistent with the Established Interferon Class – – Initial Country Launches Expected to Begin in the Coming Weeks –

Bristol-Myers Squibb får positiv CHMP-vurdering for Daklinza® (daclatasvir) for behandling av kronisk hepatitt C i EU

30-06-2014 14:00 CEST Bristol-Myers Squibb

BIOGEN IDEC AND ABBVIE ANNOUNCE POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY INVESTIGATING DACLIZUMAB HIGH-YIELD PROCESS IN MULTIPLE SCLEROSIS

17-06-2014 13:58 CEST Biogen Idec Norway AS − DAC HYP Demonstrated Superiority Over Interferon Beta-1a in Annualized Relapse Rate – − Positive Results Set Stage for Regulatory Filings –